Clinical Trial: Phase 2b/3 Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide

U.S., March 7 -- ClinicalTrials.gov registry received information related to the study (NCT07454837) titled 'Phase 2b/3 Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide' on March 02.

Brief Summary: This is a Phase 2b/3, randomized, open-label, multicenter trial evaluating the efficacy and safety of switching from bulevirtide to brelovitug for the treatment of chronic hepatitis Delta infection (CHD).

Study Start Date: Feb. 26

Study Type: INTERVENTIONAL

Condition: Chronic Hepatitis D

Intervention: DRUG: Brelovitug (BJT-778)

Brelovitug (BJT-778), 300 mg administered subcutaneously once weekly for 96 weeks.

DRUG: Bulevirtide

Bulevirtide - once daily. Brelovitug (BJT-778) - 300 mg...